Mariacarla Moleti1, Giuseppe Giuffrida2, Giacomo Sturniolo2, Giovanni Squadrito3, Alfredo Campennì4, Silvia Morelli5, Efisio Puxeddu5, Eleonora Sisti6, Francesco Trimarchi2, Francesco Vermiglio2, Michele Marinò6. 1. Dipartimento di Medicina Clinica e Sperimentale, University of Messina, Messina, Italy. mmoleti@unime.it. 2. Dipartimento di Medicina Clinica e Sperimentale, University of Messina, Messina, Italy. 3. Dipartimento di Patologia Umana dell'adulto e dell'età evolutiva, University of Messina, Messina, Italy. 4. Dipartimento di Scienze Radiologiche, Sezione di Medicina Nucleare University of Messina, Messina, Italy. 5. Dipartimento di Medicina, University of Perugia, Perugia, Italy. 6. Dipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, Italy.
Abstract
PURPOSE: Over the last years, there have been several reports on the occurrence of acute liver damage (ALD) in patients affected with Graves' ophthalmopathy (GO) receiving intravenous glucocorticoids (ivGCs). This article is aimed at reviewing the literature on this specific topic and reporting two new cases of ALD occurring in GO patients while on ivGCs. METHODS: The terms "glucocorticoid therapy" and "Graves' Ophthalmopathy"/"Graves' Orbitopathy"/"Thyroid eye disease" were used both separately and in conjunction with the terms "liver disease," "liver damage," "hepatotoxicity," "liver failure," to search MEDLINE for articles published since the first report of ALD in 2000 and up to 2015. RESULTS: ALD [defined as an increase in alanine aminotransferase (ALT) >300 U/L] during or after completion of ivGCs has been so far reported in 17 fully documented cases. Overall, one-half of those patients were diagnosed as having autoimmune hepatitis (AIH) and in the vast majority of the remaining cases a diagnosis of methylprednisolone(MP)-induced hepatotoxicity was suspected. The clinical course of liver injury varied from asymptomatic hypertransaminasemia in the vast majority of patients to fatal hepatic failure in four patients receiving higher (>8 g) cumulative doses of MP. CONCLUSIONS: The overall risk of ALD is relatively low (~1 %), and seems higher using a single dose >0.5 g and a cumulative dose >8.5 g MP. Whenever ivGC treatment is required, serum liver enzymes, viral hepatitis markers, and autoantibodies related to AIH should be obtained prior to ivGC administration. Liver function should be monitored during ivGC and up to 6 months after the end of treatment. Prolonging observation after 6 months is likely unnecessary, since all cases of ALD so far reported always occurred well within this term.
PURPOSE: Over the last years, there have been several reports on the occurrence of acute liver damage (ALD) in patients affected with Graves' ophthalmopathy (GO) receiving intravenous glucocorticoids (ivGCs). This article is aimed at reviewing the literature on this specific topic and reporting two new cases of ALD occurring in GO patients while on ivGCs. METHODS: The terms "glucocorticoid therapy" and "Graves' Ophthalmopathy"/"Graves' Orbitopathy"/"Thyroid eye disease" were used both separately and in conjunction with the terms "liver disease," "liver damage," "hepatotoxicity," "liver failure," to search MEDLINE for articles published since the first report of ALD in 2000 and up to 2015. RESULTS:ALD [defined as an increase in alanine aminotransferase (ALT) >300 U/L] during or after completion of ivGCs has been so far reported in 17 fully documented cases. Overall, one-half of those patients were diagnosed as having autoimmune hepatitis (AIH) and in the vast majority of the remaining cases a diagnosis of methylprednisolone(MP)-induced hepatotoxicity was suspected. The clinical course of liver injury varied from asymptomatic hypertransaminasemia in the vast majority of patients to fatal hepatic failure in four patients receiving higher (>8 g) cumulative doses of MP. CONCLUSIONS: The overall risk of ALD is relatively low (~1 %), and seems higher using a single dose >0.5 g and a cumulative dose >8.5 g MP. Whenever ivGC treatment is required, serum liver enzymes, viral hepatitis markers, and autoantibodies related to AIH should be obtained prior to ivGC administration. Liver function should be monitored during ivGC and up to 6 months after the end of treatment. Prolonging observation after 6 months is likely unnecessary, since all cases of ALD so far reported always occurred well within this term.
Authors: Y Koga; R Kumashiro; K Yasumoto; S Shakado; N Ono; H Noguchi; K Nagata; M Sata; H Abe; N Kaku Journal: Intern Med Date: 1992-02 Impact factor: 1.271
Authors: M Rivero Fernández; J M Riesco; V F Moreira; A Moreno; A López San Román; G Arranz; L Ruiz Del Arbol Journal: Rev Esp Enferm Dig Date: 2008-11 Impact factor: 2.086
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-06-27 Impact factor: 4.256
Authors: E Sabini; E Sisti; B Coco; M Leo; I Ionni; F Menconi; M A Profilo; B Mazzi; R Rocchi; F Latrofa; P Vitti; M Brunetto; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2016-07-27 Impact factor: 4.256
Authors: Xiantong Zou; Prakash Ramachandran; Timothy J Kendall; Antonella Pellicoro; Elena Dora; Rebecca L Aucott; Kajal Manwani; Tak Yung Man; Karen E Chapman; Neil C Henderson; Stuart J Forbes; Scott P Webster; John P Iredale; Brian R Walker; Zoi Michailidou Journal: Hepatology Date: 2018-02-22 Impact factor: 17.425
Authors: Viviana Nociti; Marco Biolato; Chiara De Fino; Assunta Bianco; Francesco Antonio Losavio; Matteo Lucchini; Giuseppe Marrone; Antonio Grieco; Massimiliano Mirabella Journal: Brain Behav Date: 2018-05-04 Impact factor: 2.708